The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
News & Trends
Procurar
Recentes
- Relatório Anual da Gestão da Disponibilidade de Medicamentos de 2024
- Bioanalytical Method Validation for Biomarkers
- MEDTECH AND DIGITAL HEALTH: A COMPREHENSIVE GUIDE TO MARKET ACCESS IN GERMANY.
- Questions & Answers for applicants, marketing authorisation holders of medicinal products and notified bodies with respect to the implementation of the Regulations on medical devices and in vitro diagnostic medical devices (Regulations (EU) 2017/745 and (EU) 2017/746)
- EMA establishes regular procedure for scientific advice on certain high-risk medical devices
- MDCG 2019-6 Rev5 Questions and answers: Requirements relating to notified bodies Revision 5 – February 2025
- Formação, Alteração e Revisão Anual de PREÇOS de MEDICAMENTOS: “Formação muito enriquecedora sobre o tema”
- EU Cosmetics Deadlines – New Rules Effective 01 February 2025